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Abstract
Introduction: In vitro and animal model of osteoarthritis (OA) studies suggest that TGF-β signalling is involved in
OA, but human data is limited. We undertook this study to elucidate the role of TGF-β signalling pathway in OA by
comparing the expression levels of TGFB1 and BMP2 as ligands, SMAD3 as an intracellular mediator, and MMP13 as a
targeted gene between human osteoarthritic and healthy cartilage.
Methods: Human cartilage samples were collected from patients undergoing total hip/knee joint replacement
surgery due to primary OA or hip fractures as controls. RNA was extracted from the cartilage tissues. Real-time
quantitative PCR was performed to measure gene expression. Mann-Whitney test was utilized to compare the
expression levels of TGFB1, BMP2, SMAD3 and MMP13 in human cartilage between OA cases and controls.
Spearman’s rank correlation coefficient (rho) was calculated to examine the correlation between the expression
levels of the four genes studied and non-parametric regression was used to adjust for covariates.
Results: A total of 32 OA cases (25 hip OA and 7 knee OA) and 21 healthy controls were included. The expression
of TGFB1, SMAD3, and MMP13 were on average 70 %, 46 %, and 355 % higher, respectively, whereas the expression
of BMP2 was 88 % lower, in OA-affected cartilage than that of controls (all p < 0.03), but no difference was observed
between hip and knee OA (all p > 0.4). The expression of TGFB1 was correlated with the expression of SMAD3
(rho = 0.50, p = 0.003) and MMP13 (rho = 0.46, p = 0.007) in OA-affected cartilage and the significance became
stronger after adjustment for age, sex, and BMI. The expression of BMP2 was negatively correlated with both TGFB1
(rho = −0.50, p = 0.02) and MMP13 (rho = −0.48, p = 0.02) in healthy cartilage, but the significance was altered after
adjustment for the covariates. There was no correlation between the expression of SMAD3 and MMP13.
Conclusions: Our results demonstrate that MMP13 expression is associated with an increased expression of TGFB1
in OA-affected cartilage, possibly through SMAD-independent TGF-β pathway. Furthermore, TGF-β/SMAD3 is
overactivated in OA cartilage; yet, the consequence of this overactivation remains to be established.
Introduction
Osteoarthritis (OA), the most common rheumatic condi-
tion, is primarily a disease of articular cartilage and sub-
chondral bone [1]. It presents with joint pain, stiffness,
deformity, and joint failure at advanced stage [2], and
imposes a high socio-economic burden on society [3].
Although the pathogenesis of OA remains elusive, mount-
ing evidence suggests that transforming growth factor
β (TGF-β) signalling plays a role in the development
of OA [4].
TGF-β signalling is involved in diverse cellular pro-
cesses including proliferation, differentiation, migration
and apoptosis, as well as extracellular matrix (ECM) syn-
thesis and degradation [5]. It plays a critical role in the
development, homeostasis, and repair of the cartilage
[4]. Population-based association studies have identified
genetic variants in different components of TGF-β sig-
nalling to be associated with OA. A single nucleotide
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polymorphism (SNP; T29 > C) in the transforming
growth factor beta 1 (TGFB1) gene was reported to be
associated with incidence of spinal osteophyte forma-
tion in a Japanese population [6]. SNPs, rs2278422 and
rs8179181, located in the 6th intron of TGFB1, have been
associated with knee and hip OA susceptibility in a British
Caucasian population [7]. Camurati–Engelmann disease
(CED), which presents with long bone steosclerosis, is
caused by mutations in TGFB1, which lead to elevated
TGF-β1 activity [8].
The asporin gene (ASPN) has been shown to inhibit
TGF-β signalling-mediated synthesis of cartilage-specific
ECM components, such as type II collagen (COL2A1)
and aggrecan (AGC1) in chondrocytes [9]. The aspartic
acid (D) repeat polymorphism in ASPN has been associ-
ated with OA in Asian populations [9, 10]. When com-
pared to common ASPN D13 allele, the D14 allele was
found to be overrepresented in knee and hip OA patients,
relative to healthy controls [9], resulting in greater inhibi-
tory effects on TGF-β-induced expression of AGC1 and
COL2A1 [11]. Additionally, the ASPN variant, rs13301537,
was recently reported to contribute to knee OA risk in the
Chinese Han population [12].
Apart from TGFB1, other components of the TGF-β
signalling pathways have also reported to be associated
with OA. Growth differentiation factor 5 (GDF5), a
member of the TGF-β superfamily, has been associated
with OA in Asian and European populations [12–14].
The risk allele (T) in SNP rs143383 (T/C), located in the
promoter of GDF5, was found to confer lower GDF5
transcription activity both in vitro and human cartilage
[13, 15]. Mutations in the GDF5 gene have also been as-
sociated with other skeletal disorders such as congenital
hip dysplasia, Hunter-Thompson-type acromesomelic
dysplasia, type C brachydactyly, and Grebe-type chon-
drodysplasia [4, 16].
In an attempt to replicate OA-associated loci in the
Newfoundland and Labrador population, we reported an
association between SNP rs1049007 located in the bone
morphogenetic protein 2 (BMP2) gene and OA [17].
BMP2 is also a member of the TGF-β superfamily. Given
the SNP is a synonymous polymorphism, what the rela-
tionship between the SNP and OA is remains to be dis-
covered. Mutations in mothers against decapentaplegic
homolog 3 (SMAD3), one of the intracellular mediators
of TGF-β signalling, are known to cause the aneurysm-
osteoarthritis syndrome, presenting with early-onset
polyarticular OA [18]. In our previous study we found a
SNP in the last intron of SMAD3 to be associated
with the total burden of radiographic OA [19], al-
though the exact mechanism for the association needs
to be established.
However, most of these studies focused on a single
gene at a time. Given that those genetic variants are not
functional, how these genes exert their effect on OA re-
mains to be investigated. We, therefore, undertook the
current study to elucidate the role of TGF-β signalling
pathway in OA by simultaneously examining the expres-
sion levels and pair-wise correlations of four genes in-
cluding TGFB1 and BMP2 as ligands, SMAD3 as an
intracellular mediator, and matrix metallopeptidase 13
(MMP13) as a targeted gene in human cartilage tissues
obtained from OA patients and healthy controls.
Methods
Subjects
The study was part of the ongoing Newfoundland
Osteoarthritis Study (NFOAS) that was initiated in 2011,
aiming at identifying novel genetic, epigenetic, and bio-
chemical markers for OA [20]. OA patients were re-
cruited from those who underwent total knee or hip joint
replacement due to primary OA between November 2011
and December 2013 in St. Clare’s Mercy Hospital and
Health Science Centre General Hospital in St. John’s, the
capital city of Newfoundland and Labrador (NL), Canada.
Healthy controls were recruited from the same hospitals
from those who underwent hemi-arthroplasty of the hip
due to fractures of the femoral neck but did not have evi-
dence of hip OA based on their hip X-ray data, which
were further confirmed by pathological examination on
the removed femoral head cartilage. OA diagnosis was
made based on the American College of Rheumatology
criteria [21, 22], and the judgement of the attending
orthopaedic surgeons. The pathology reports on the re-
moved cartilage were reviewed for all subjects to ensure
the accuracy of the diagnosis and the status of any cartil-
age degeneration in the controls. The consent rate of the
study was 90 %. The study was approved by the Health
Research Ethics Authority (HREA) of Newfoundland and
Labrador and a written consent was obtained from all
study participants.
Demographics and anthropometrics
Demographic information was obtained by a self-
administered questionnaire with the help of the research
staff, if necessary. Anthropometric data including height
and weight was retrieved from their hospital admission
and medical records and body mass index (BMI) was cal-
culated by dividing weight in kilograms by squared height
in meters. Age was calculated at the time of the surgery.
RNA isolation
Four pieces (approximately 200 mg each) of cartilage tis-
sues were retained from either the tibial plateau or fem-
oral heads during the surgery. The samples were then
flash frozen and stored in liquid nitrogen until the ex-
periment. Up to 200 mg frozen cartilage tissue was
transferred to the homogenizing cylinder with 1 ml
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TRIzol lysis reagent and 200 μl guanidine thiocyanate
and homogenized using a cryogenic mill (Spex Freezer
Mill, model 6770, Metuchen, NJ, USA) with the follow-
ing parameters: two cycles of 2 min grinding at max-
imum frequency with 10 min cooling down between
grinding cycles. The homogenate was then transferred to
a new 2 ml RNase-free tube and incubated for 5 min at
room temperature. RNeasy Lipid Tissue Mini Kit (Qia-
gen, Venlo, Netherlands) was used for extracting total
ribonucleic acid (RNA) from the aqueous phase as per
the manufacturers’ protocol.
Gene expression measurement
Complementary DNA (cDNA) synthesis from the extracted
RNA was done using Maxima H Minus First Strand cDNA
Synthesis Kit (K1682, Vilnius, Lithuania). One hundred ng
of RNA from each sample was primed with random
primers before addition of a reverse-transcription solution
[5x buffer, Ribolock, 500 μM deoxyribose nucleoside tri-
phosphates (dNTPs) (Life Technologies, Carlsbad, CA,
USA) Maxima polymerase]. One μl of synthesized cDNA
was subject to quality control by polymerase chain reac-
tion (PCR) amplification of the target genes and glyceral-
dehyde 3-phosphate dehydrogenase (GAPDH) followed by
agarose gel electrophoresis.
Expression quantification of the genes studied was per-
formed using ABI 7900HT Fast Real-Time PCR System
on 96-well plate. GAPDH was used as an internal refer-
ence gene to normalize the relative quantification of the
targeted genes—TGFB1, BMP2, SMAD3, and MMP13.
Amplification primers were designed using The National
Center for Biotechnology Information (NCBI) primer-
blast tool for the shortest isoforms of the genes and the
sequences were blasted in NCBI Basic Local Alignment
Search Tool (BLAST) tool to ensure 100 % coverage of
all the isoforms, as well as minor similarly to other gen-
omic sequences. Primers were validated using a 4-point
dilution series of two random cDNA samples. Table 1
presents the primer sequences used and the size of PCR
products. qPCR was then performed in triplicate using
SYBR Green (Power SYBR® Green PCR Master Mix,
4367659, Applied Biosystems, Carlsbad, CA, USA), and
forward and reverse primers in a final volume of 20 μl.
Cycling conditions were: 95 °C for 10 min, 95 °C for
15 sec, and 60 °C for 1 min, repeated in 45 cycles,
followed by melt-curve analysis. One of the control sam-
ples was selected as calibrator and the relative quantifi-
cation (RQ) of the target gene expression in each sample
was calculated as fold changes in relation to the calibra-
tor using Livak method [23].
Statistics
Descriptive statistics was summarized using either mean
or percentage and comparisons between OA cases and
controls were performed using Student’s t test or chi-
square test wherever appropriate. Mann-Whitney test was
utilized to compare gene expression levels between OA
cases and controls. Spearman’s rank correlation coefficient
(rho) was calculated to examine the correlation between
the expression levels of the four genes studied and non-
parametric regression model was used to adjust for poten-
tial confounding factors including age, sex, and BMI. The
association between each of the genes studied and the co-
variates including age, sex, and BMI were also examined.
All the statistical analysis was conducted using STATA/SE
11.2 (Stata Corp, College Station, TX, USA). Significance
level was defined as at α level of 0.05 without making ad-
justment for multiple comparisons because it is preferable
in this case since the data under evaluation are not ran-
dom numbers but actual observations [24].
Results
A total of 53 study participants were included in the
study: 32 (7 knee OA and 25 hip OA) OA cases and 21
healthy controls. All of them were Caucasians. Seventy
percent of the study participants were females and 30 %
were males. Controls were on average 12 years older
than OA cases (p = 0.0002) and had a lower BMI than
OA cases (p < 0.0001). Table 2 presents the characteris-
tics of the study population.
Gene expression differences between OA and controls
Pathological reports on the cartilage confirmed the sta-
tus of all the OA cases. It also found that 14 controls
Table 1 Primers used in qPCR experiments
Primer sequence (5′ > 3′) Product size
SMAD3 reverse primer GGCTCGCAGTAGGTAACTGG 91 bp
SMAD3 forward primer GCATGGACGCAGGTTCTCC
TGFB1 reverse primer CTCAATTTCCCCTCCACGGC 114 bp
TGFB1 forward primer TCCTGGCGATACCTCAGCAA
MMP13 reverse primer AGGTAGCGCTCTGCAAACTGG 92 bp
MMP13 forward primer AGCTGGACTCATTGTCGGGC
BMP2 reverse primer CTTGCGCCAGGTCCTTTGAC 111 bp
BMP2 forward primer CCACCATGGTCGACCTTTAGGA
GAPDH reverse primer TCGCCCCACTTGATTTTGG 106 bp
GAPDH forward primer GCAAATTCCATGGCACCGT
qPCR quantitative polymerase chain reaction
Table 2 Characteristics of the study populationa
Controls (n = 21) OA (n = 32) p
Age (yrs) 76.45 ± 10.93 64.30 ± 10.43 0.0002
BMI (kg/m2) 23.79 ± 1.03 32.25 ± 1.35 <0.0001
Sex (% females) 76 % 66 % 0.4
OA osteoarthritis, BMI body mass index
aValues are expressed as mean ± standard deviation, unless indicated otherwise
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had healthy intact cartilage, but 7 other controls had
age-related minor degenerative changes in their cartil-
age. We therefore compared the differences in the ex-
pression of the four genes between the healthy intact
cartilage samples and those with age-related minor de-
generative changes in the controls. We found that there
was no difference (all p > 0.2; Table 3). Then, we com-
pared the expression of the four genes between hip and
knee OA cases; again, we found no difference (all p >
0.13; Table 3). Consequently, we combined hip OA and
knee OA together and compared them with the data
from all 21 controls.
We found that all four genes were expressed in OA-
affected and healthy cartilage. The expression of TGFB1,
SMAD3 and MMP13 was on average 70 %, 46 %, and
355 % higher, respectively, whereas the expression of
BMP2 was 88 % lower, in OA-affected cartilage than that
in controls (all p < 0.03) (Fig. 1).
The expressions of TGFB1, BMP2, and MMP13 were
not associated with age, sex, and BMI either in OA
cases or in controls (all p > 0.09). However, we found
that the expression of SMAD3 was correlated with age
(rho = −0.35, p = 0.05) and BMI (rho = 0.38, p = 0.03).
SMAD3 was also expressed higher in females than in
males (48 % higher, p = 0.04). These differences were
only observed in individuals with OA but not between
controls.
Relationship between TGFB1, BMP2, SMAD3, and MMP13
expression
We found that the expression of TGFB1 was significantly
correlated with the expression of SMAD3 (rho = 0.50, p =
0.003) and MMP13 (rho = 0.46, p = 0.007) in OA-affected
cartilage but not in healthy cartilage (Table 4). The signifi-
cance became even stronger after adjustment for age, sex,
and BMI (p = 0.002 and p < 0.0001, respectively).
We also found that the expression of BMP2 was nega-
tively correlated with both TGFB1 (rho = −0.50, p = 0.02)
and MMP13 (rho = −0.48, p = 0.02) in healthy cartilage
but not in OA-affected cartilage (Table 4). However, the
significances were altered after adjustment for age, sex,
and BMI.
We found there was no correlation between the ex-
pression of SMAD3 and MMP13 either in OA-affected
cartilage or controls (Table 4).
Discussion
To the best of our knowledge, this is the first study of
using human cartilage samples to demonstrate a signifi-
cant association between the expression of TGFB1 and
MMP13; suggesting TGF-β signalling pathway switches its
protective role in normal cartilage observed from in vitro
studies [4], to a damaging factor in advanced OA, possibly
through SMAD-independent TGF-β pathway.
Evidence from animal models of OA indicates that in-
creased expression of TGFB1 is involved in OA develop-
ment. Multiple intra-articular injections of TGF-β in
mice joint results in changes to articular cartilage with
strong resemblance to both experimental and spon-
taneous mice OA [25]. High concentrations of active
TGFB1 in the mice subchondral bone is reported to ini-
tiate osteoarthritic changes in the bone and cartilage
[26], and induced expression of TGFB1 from the syn-
ovial lining layers results in OA-like changes in the mur-
ine knee joint including hyperplasia of synovium and
chondro-osteophyte formation [27]. Data from human
joint tissue, however, are limited. Pombo-Suarez et al.
[28] studied cartilage samples obtained from 11 patients
with hip OA and 11 patients with femoral neck fracture
and found that all three TGFB isoforms including
TGFB1 were significantly and highly expressed in osteo-
arthritic cartilage. Our results are consistent with theirs,
demonstrating a 70 % increase in TGFB1 expression in
OA-affected cartilage. Since we only measured mRNA
expression of TGFB1, our results may not reflect the
corresponding protein levels. Pombo-Suarez et al. [28]
found that the increased messenger RNA (mRNA) levels
of TGFB isoforms was in relation to an increased per-
centage of TGF-β-positive staining chondrocytes, indi-
cating that mRNA expression of TGFB isoforms is well
correlated to their protein levels. However, Wu et al.
[29] performed a proteomic analysis of articular cartilage
from 7 knee OA and 7 healthy controls and found a 16-
fold decreased protein expression of TGFB1 in OA
Table 3 Gene expression comparison between hip vs. knee OA, and intact healthy cartilage vs. cartilage with minor degeneration in
controlsa
Gene Hip OA Knee OA p Healthy controls Controls with minor degeneration p
(n = 7) (n = 25) (n = 14) (n = 7)
TGFB1 6.40 ± 2.16 5.71 ± 2.51 0.42 3.35 ± 1.74 4.36 ± 1.89 0.20
SMAD3 2.55 ± 1.59 2.62 ± 0.76 0.56 1.84 ± 1.46 1.60 ± 1.14 1.00
MMP13 1.74 ± 2.21 0.90 ± 0.74 0.53 0.31 ± 0.53 0.41 ± 0.80 0.82
BMP2 0.15 ± 0.02 0.08 ± 0.01 0.13 1.17 ± 0.31 1.23 ± 0.46 0.65
OA osteoarthritis
aFigures are relative quantification (RQ) mean ± standard deviation
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cartilage, suggesting the effect of TGFB1 in OA may be
joint specific. We included cartilage samples from both
knee and hip OA patients but did not find any difference
in the mRNA expression of these three genes. The rea-
son for the discrepancy between our results and Wu’s
[29] is unclear. However, possible reasons leading to
false positives include sampling bias due to different
population sources, control cartilage of unspecified ori-
gin, and the utilization of less stringent significance level
(raw p value < 0.03) given the large number of proteins
(n = 814) examined in their study. Furthermore, apart
from TGF-β1, no other protein involved in the TGF-β
signalling was found to be significantly different, indicat-
ing caution should be used in interpreting their results.
Verdier et al. [30] reported that expression levels could
vary, based on the OA stage and the level of involve-
ment. In the immunohistochemical analysis of cartilage
tissues obtained from six hip OA patients and four con-
trols TGF-β1 staining was increased in slightly altered
areas, reduced in more degraded cartilage, but markedly
increased in the osteophytes, suggesting TGFB1 may
take part in the hypertrophic stage of the OA process.
Unfortunately, we do not have cartilage severity data to
assess the distribution of TGFB1 expression in different
layers of cartilage.
The consequence of increased TGFB1 activity is un-
known. In vitro studies showed that activity of TGF-β
sub-pathway had a protective role in articular cartilage
[4]. However, Pombo-Suarez et al. [28] found that none
of the expression levels of the three isoforms of TGF-β
were correlated with the expressions of main proteins in
human cartilage, i.e., COL2A1 and AGC1, suggesting the
expected role of TGF-β pathway is altered in human OA
cartilage. Moldovan et al. [31] found that TGF-β can up-
regulate the levels of MMP13 in cultured cartilage ex-
plants and cause a mimicking of the in situ distribution
of the increased MMP13 observed in both OA- and
rheumatoid arthritis-affected cartilage. Our results are
consistent with theirs with a strong correlation between
expressions of TGFB1and MMP13 in OA-affected cartil-
age, suggesting TGF-β switches from a protective role
observed from in vitro studies to a damaging factor in
OA-affected cartilage. Similar phenomenon has also
been reported for other tissues including squamous car-
cinoma [32], breast cancer [33], human gingival fibro-
blasts [34] and osteoblasts [35].
MMP13 is a major enzyme targeting cartilage for the
degradation of types II, IV, and IX collagen, proteogly-
can, osteonectin and perlecan [36]. Its overexpression
has been shown to be related to cartilage destruction
among both human OA patients and animal models of
OA [37]. It seems that TGF-β signalling regulates ex-
pression of MMP13 through SMAD-dependent pathway
in squamous carcinoma cells [32], and in human gingival
fibroblasts [34]. In mice primary chondrocytes TGF-β
signals through SMAD3 rapidly repress MMP13 expres-
sion, but induce its expression in the absence of SMAD3
[38]. Alternatively, TGF-β has been described as increas-
ing MMP13 expression in osteoblast cells through a
Fig. 1 Comparison of the expression levels of BMP2, TGFB1, SMAD3, and MMP13 in human cartilage between osteoarthritis (OA) cases and controls.
p values were from Mann-Whitney test
Table 4 Spearman’s correlation coefficients (rho) between the
expression of TGFB1, BMP2, SMAD3, and MMP13 in OA-affected
and healthy cartilage, respectively
Controls (N = 21) OA (N = 32)
TGFB1 and SMAD3 rho = 0.07, p = 0.7 rho = 0.50, p = 0.003
TGFB1 and MMP13 rho = 0.28, p = 0.2 rho = 0.46, p = 0.007
SMAD3 and MMP13 rho = 0.05, p = 0.83 rho = 0.15, p = 0.39
BMP2 and TGFB1 rho = −0.50, p = 0.02 rho = 0.24, p = 0.21
BMP2 and MMP13 rho = −0.48, p = 0.03 rho = 0.17, p = 0.35
OA osteoarthritis
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combination of SMAD-dependent and SMAD-independent
pathways [35]. In the current study we found there was no
correlation between SMAD3 and MMP13 expression in
either normal or OA cartilage, suggesting that the as-
sociation between TGFB1 and MMP13 expression in
OA-affected cartilage is primarily through the SMAD-
independent pathway.
TGF-β receptors can exert their effect through collateral
signalling via mitogen-activated protein kinase (MAPK)
and phosphoinositide 3-kinase (PI3K) proteins [39]. The
biochemical blockade of MAPK pathway abolishes TGF-β
induction of MMP13 in human breast cancer cell lines
[33], and the inhibition of the MAPK pathways reduces
TGFB1-stimulated MMP13 expression in the rat osteosar-
coma cell line (UMR 106-01) [35], favouring the SMAD-
independent pathway for enhanced MMP13 expression in
OA cartilage. The regulation might also occur through
other mechanisms including inflammatory factors. It is re-
ported that TGF-β1 treatment increases the expression
of pro-inflammatory cytokines, including interleukin-1
(IL-1) and metalloproteinase-1 in synovial fibroblasts
from rheumatoid arthritis and normal individuals [40],
and IL-1 secretion by chondrocytes has shown to stimu-
late MMP13 expression and cartilage degradation in OA
[41]. Our data also showed that the increased expression
in MMP13 was disproportional to the increased TGFB1
expression, suggesting other factors may also play a role in
increasing MMP13 expression in OA cartilage. Blaney
Davidson et al. showed that an increase in activin A
receptor type II-like 1 (ALK1) expression [bone morpho-
genetic protein (BMP) pathway receptor] was associated
with elevated MMP13 expression in human osteoarthritic
cartilage [42], suggesting BMP sub-pathway may also be
involved in the regulation ofMMP13 expression in human
cartilage. In the current study, we found that BMP2 ex-
pression was negatively associated with both TGFB1 and
MMP13 expression in healthy cartilage, suggesting that
BMP2 can inhibitMMP13 expression either directly or in-
directly, but this inhibitory effect was disappeared because
of the reduced BMP2 expression in OA-affected cartilage.
However, the significant correlation between BMP2 and
TGFB1/MMP13 was altered after adjustment for potential
confounding factors. Sample size might be to blame. We
conducted a post hoc power calculation using data on
SMAD3 which had the smallest effect size in our study.
For the given sample size and the observed effect size, we
had 100 % study power at both α = 0.05 and 0.01. An inde-
pendent study is needed to confirm the effect of BMP
pathway in regulation ofMMP13 expression.
Although SMAD3 appeared not to be associated with
MMP13 expression in our study, its expression was
highly correlated with TGFB1 and was increased in OA
cartilage compared to controls, suggesting that TGF-β/
SMAD3 signalling is also overactivated in OA. This
enhanced activity may indicate a reparative response by
chondrocytes to the cartilage damage resulting from OA
progression, through TGF-β/SMAD3 signalling. While
TGF-β signals through Smad1/5/8 route are shown to
result in deleterious cartilage response, the signals
through SMAD2/3 are mainly protective, which indi-
cates that TGF-β/SMAD3 signalling is essential for the
cartilage maintenance [43]. In line with this, decreased
phosphorylation of SMAD3, an indication of decreased
signalling activity, has been reported during OA progres-
sion of murine models of OA [44, 45], and SMAD3
knockout mice have shown to develop OA-like features
in their joints [46]. Further studies are needed to eluci-
date the consequence of the overactivity of TGF- β/
SMAD3 pathway.
The strength of the current study is the use of human
cartilage rather than animal models or cultured cells, thus
having a direct application to OA patients. However, we
only studied cartilage tissue, limiting the generalizability
of the findings to other joint tissues involved in OA.
mRNA expression levels may not reflect the correspond-
ing protein levels, but previous studies found that mRNA
levels of TGFB1 was well correlated with its protein
levels [31], suggesting this is not a concern. However,
our study is cross-sectional and we cannot conclude a
causal relationship.
Conclusions
We demonstrated that TGFB1 switches its protective role
as observed using in vitro studies to a damaging factor in
human OA cartilage, leading to an increased expression of
MMP13, possibly through SMAD-independent path-
way. Further, we found that TGF-β/SMAD3 pathway
was also overactivated, but the consequence needs to
be established.
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